Similar to GABA A receptor-channels the calciummediated gating of the small-conductance K Ca 2 and the intermediate-conductance K Ca 3.1 channels can be positively or negatively modulated by small molecule drugs, which, in analogy to the GABA field, have been termed positive (PAM) or negative allosteric modulators. While positive gating modulators like EBIO, NS309, SKA-31 and SKA-121 shift the calciumresponse curve of these voltage-independent, calmodulin-gated channels to the left and apparently increase their sensitivity to calcium, negative gating modulators decrease calcium sensitivity. 1 However, in contrast to GABA A receptors, where the binding site for the endogenous ligand GABA is located on the extracellular side and where allosteric modulation by benzodiazepines, neurosteroids and barbiturates has been studied in exquisite detail, only a small number of studies have been performed for K Ca channels. One reason is of course the lower level of pharmacological interest. While GABA A receptors are firmly established as clinically used drug targets, no K Ca 2 or K Ca 3.1 channel modulators have yet reached the clinic despite their undeniable therapeutic potential for neurological, cardiovascular and inflammatory diseases. 1 Another reason is the technical challenge involved in studying K Ca channel gating. The gating apparatus is located at the intracellular C-terminus, where calmodulin, which functions as a calcium-sensing b-subunit, is constitutively associated with the calmodulin binding domain of the channels, 2 necessitating the performance of inside-out patch-clamp recordings when aiming to work at defined intracellular calcium concentrations. Nevertheless, a few studies, including some exquisite X-ray crystallography, 3, 4 have been performed and it is currently hypothesized that K Ca channel PAMs bind at the interface between the calmodulin N-lobe and the calmodulin-binding domain of the channels and thus "facilitate" mechanical opening ( D increased open channel probability) at a given Ca 2C concentration. Both benzimidazole-type activators like EBIO and NS309 and naphthothiazole/oxazole-type activators like SKA-31 and SKA-121 ( Fig. 1) have been shown to bind in this interface pocket either through co-crystallization of calmodulin in complex with the calmodulin-binding domain of K Ca 2.2, 3, 4 or, more recently, by our own group using a combination of electrophysiology and site-directed mutagenesis. 5 The latter study was guided by homology modeling of the K Ca 2.3 and K Ca 3.1 interface pocket and docking studies using the RosettaLigand computational modeling software. While the crystallography studies 3, 4 afforded the first insight into the atomistic mechanism of action of K Ca activators, our molecular modeling study provides a plausible explanation for why K Ca channel activators in general are 5-10-fold more potent in activating K Ca 3.1 than K Ca 2 channels. 5 The presence of R362 creates an extensive "background" hydrogen-bond network in the K Ca 3.1 interface pocket that stabilizes the main contacts NH 2 -substituted K Ca activators make with M51 and E54 in calmodulin (Fig. 1) . The three K Ca 2 channels have shorter N or S residues in the corresponding position and therefore cannot form this hydrogen-bond network. The Rosetta models further suggested an explanation for why the 5-position methyl substituted SKA-121 is more potent on K Ca 3.1 and less potent on K Ca 2.3 than its parent compound SKA-31 by identifying an increased number of hydrophobic interactions in the "back" of the interface pocket for SKA-121 in the most frequently sampled lowest energy binding poses in K Ca 3.1.
While these homology models are certainly helpful for explaining selectivity or for attempting structure based drug design, they fail to explain the experimentally observed ability of SKA-121 to further potentiate K Ca currents at saturating Ca 2C concentrations. All previously published calcium-response curves for EBIO or NS309 on K Ca 2.2 show a "clean" left-ward shift without any increase in maximal effect (Fig. 1) . SKA-121, in contrast, doubles K Ca 3.1 currents even in the presence of 10 mM of free intracellular calcium. This potentiation above the effect of the endogenous ligand, which is reminiscent of the superagonism observed on extrasynaptic GABA A receptors, could potentially be explained by the assumed relatively low Ca 2C -dependent P o (max) of K Ca 3.1. However, it becomes harder to explain for K Ca 2.3, where SKA-121 is also still able to further potentiate currents in the presence of even 30 mM free calcium 5 despite the fact that K Ca 2 channels are supposedly already fully open.
Future studies of K Ca channel gating and the mechanism of action of K Ca activators therefore will have to address several questions. First, how does the calmodulin mediated gating of the channels actually work? The dimer-of-dimers model suggested by the C-terminal crystal structures, 3, 4, 6 which all show two anti-parallel K Ca 2.2 fragments and two anti-parallel calmodulins forming a dimeric complex, has been questioned in favor of a model with four-fold rotational symmetry. 7 This debate is unlikely to be resolved before a fulllength structure of a K Ca 2 or K Ca 3.1 channel becomes available. Second, how do small molecules affect the gating and do they have the same effects on K Ca 3.1 and K Ca 2 channels? Up to now our laboratory is the only group that published K Ca 3.1 calcium-response curves in the presence of a K Ca activator raising the question whether there are intrinsic differences between K Ca 3.1 and K Ca 2 channels, for which phosphatidylinositol 4,5-bisphosphate (PIP 2 ) has recently been shown to regulate channel activity by binding to the K Ca 2.2 calmodulin-binding domain/calmodulin complex. 8 3) Are there superagonists and partial agonists for K Ca channels? And lastly, how different are K Ca agonists that bind in the C-terminal interface pocket from K Ca agonists 1 that bind in the pore domain?
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